MARKET

MNOV

MNOV

MediciNova Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.490
-0.160
-3.44%
After Hours: 4.570 +0.08 +1.78% 17:57 04/16 EDT
OPEN
4.660
PREV CLOSE
4.650
HIGH
4.660
LOW
4.385
VOLUME
474.38K
TURNOVER
--
52 WEEK HIGH
13.25
52 WEEK LOW
4.385
MARKET CAP
218.58M
P/E (TTM)
-14.3910
1D
5D
1M
3M
1Y
5Y
MediciNova to Participate in the UBS Global Healthcare Virtual Conference
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will participate in the UBS Global Healthcare Virtual Conf...
GlobeNewswire · 3d ago
Pulmonary Fibrosis Drugs Market by Technology & Application – Analysis & Global Forecast to 2028
AmericaNewsHour · 3d ago
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)
Benzinga · 4d ago
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Benzinga · 4d ago
MNOV: BARDA Contract to Support Development of MN-166 in ARDS…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update BARDA Contract to Support MN-166 Development for Chlorine Gas-Induced Lung Injury On March 9, 2021, MediciNova, Inc. (NASDAQ:MNOV) announced a partnership with the Biomedica...
Zacks Small Cap Research · 03/15 09:35
MVIS, RIDE, XXII and MRKR among midday movers
Gainers: NLS Pharmaceutics (NLSP) +87%.Entera Bio (ENTX) +72%.Seelos Therapeutics (SEEL) +69%.Ebang International (EBON) +43%.Perpetua Resources (PPTA) +27%.AMREP (AXR) +21%.22nd Century (XXII) +19%.Aemetis (AMTX) +18%.LendingClub (LC) +18%.MicroVision (MV...
Seekingalpha · 03/12 17:43
Ulta Beauty, Chargepoint Holdings leads the premarket losers' pack
Marker Therapeutics (MRKR) -24% after prices stock offering.Timber Pharmaceuticals (TMBR) -25%.Evoke Pharma (EVOK) -24% on Q4 earnings release.FinVolution (FINV) -15%.Poshmark (POSH) -15% on Q4 earnings release; after Q1 revenue guidance falls short.AMMO (...
Seekingalpha · 03/12 13:46
DJ MediciNova Shares Drop 18% After Wednesday Run-Up
Dow Jones · 03/11 18:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MNOV. Analyze the recent business situations of MediciNova Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MNOV stock price target is 17.63 with a high estimate of 26.50 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 75
Institutional Holdings: 12.51M
% Owned: 25.70%
Shares Outstanding: 48.68M
TypeInstitutionsShares
Increased
20
1.30M
New
12
245.25K
Decreased
14
138.74K
Sold Out
8
145.74K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
Jeffrey Himawan
President/Chief Executive Officer/Director
Yuichi Iwaki
Chief Financial Officer
Edward Stepanow
Vice President/IR Contact Officer
Geoffrey O'Brien
Vice President/IR Contact Officer
Geoffrey O'brien
Other/Director
Kazuko Matsuda
Director
Carolyn Beaver
Independent Director
Hideki Nagao
No Data
About MNOV
Medicinova, Inc. is a biopharmaceutical company. The company is focused on developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The Company is developing activities on MN-166 (ibudilast) for neurological disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction (methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company’s pipeline includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Webull offers kinds of MediciNova, Inc. stock information, including NASDAQ:MNOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNOV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNOV stock methods without spending real money on the virtual paper trading platform.